Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Clinical trial NCT04351334 · COMPLETED

Trial details

NCT number: NCT04351334
Sponsor: Pfizer
Status: COMPLETED
Study type: OBSERVATIONAL

Non-Small-Cell Lung Carcinoma

Start date: 2020-03-01
Primary completion: 2022-11-01
Enrollment: 161

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.